Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-2879bea9059649bf46970484a32311c1",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-2879bea9059649bf46970484a32311c1",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-2879bea9059649bf46970484a32311c1",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-2879bea9059649bf46970484a32311c1\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-2879bea9059649bf46970484a32311c1</b></p><a name=\"composition-en-2879bea9059649bf46970484a32311c1\"> </a><a name=\"hccomposition-en-2879bea9059649bf46970484a32311c1\"> </a><a name=\"composition-en-2879bea9059649bf46970484a32311c1-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1565/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ryeqo</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/21/1565/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp2879bea9059649bf46970484a32311c1"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - ryeqo",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Ryeqo is and what it is used for</li><li>What you need to know before you take Ryeqo</li><li>How to take Ryeqo</li><li>Possible side effects</li><li>How to store Ryeqo</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What ryeqo is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What ryeqo is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Ryeqo contains the active substances relugolix, estradiol and norethisterone acetate.</p><p>It is used to treat</p><ul><li>moderate to severe symptoms of uterine fibroids (commonly known as myomas), which are non-cancerous tumours of the uterus (womb).</li><li>symptoms associated with endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (endometriosis is an often painful disorder in which tissue similar to the tissue that normally lines the inside of your uterus - the endometrium - grows outside your uterus).</li></ul><p>Ryeqo is used in adult women (over 18 years of age) before they reach menopause.</p><p>In some women, uterine fibroids may cause heavy menstrual bleeding (your period ) and pelvic pain (pain below the belly button). Ryeqo is used for the treatment of your fibroids to stop or reduce bleeding and to decrease pain and pelvic discomfort associated with uterine fibroids.</p><p>Women with endometriosis can experience pelvic or lower abdominal pain, pain with menstrual periods and pain with intercourse. Ryeqo is used for the treatment of endometriosis to decrease the symptoms due to displaced tissue of the lining of the womb.</p><p>This medicine contains relugolix, which blocks certain receptors in the brain and this reduces the production of hormones that in turn stimulate the ovaries to produce estradiol and progesterone. When blocked, the levels of estrogen and progesterone circulating in the body are reduced. This medicine also contains two types of female hormones, estradiol which belongs to a group of medicines called estrogens and norethisterone which belongs to a group of medicines called progestogens. The inclusion of these hormones in Ryeqo maintains a hormonal state similar to the beginning of your menstrual cycle and thus relieves your symptoms while helping to protect the strength of your bones.</p></div>"
}
},
{
"title" : "2. What you need to know before you take ryeqo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take ryeqo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Ryeqo Do not take Ryeqo if you have any of the conditions listed below.<br/>If you do have any of the conditions listed below, you must tell your doctor:</p><p>if you are allergic to relugolix, estradiol, norethisterone acetate or any of the other ingredients of this medicine (listed in section 6).</p><p>if you have or previously have had a blood clot in a blood vessel in the legs (deep vein thrombosis), lungs (pulmonary embolism), heart (heart attack), brain (stroke) or any other parts of the body.</p><p>if you have or previously have had a disease caused by blood clots in the arteries, such as a heart attack, stroke or angina.</p><p>if you have a blood clotting disorder (such as protein C deficiency, protein S deficiency, antithrombin-III deficiency, or Factor V Leiden).</p><p>if you have osteoporosis.</p><p>if you suffer from headaches with focal neurological symptoms such as paralysis or loss of muscle control, or migraines with visual disturbance.</p><p>if you have any type of cancer which might be made worse by exposure to female sex hormones, such as cancer of the breast or the genital organs.</p><p>if you have or ever had liver tumours.</p><p>if you have or ever had a liver disease and your liver function tests have not returned to normal.</p><p>if you are pregnant or if you think you might be pregnant or if you are breastfeeding.</p><p>if you have any genital bleeding of unknown origin.</p><p>if you are taking hormonal contraception (for example birth control pills) and unwilling to discontinue its use.</p><p>If any of the above conditions appear for the first time while taking Ryeqo, stop taking it at once and consult your doctor immediately.</p><p>If you are not sure about any of the points above, talk to your doctor before taking Ryeqo.</p><p>Warnings and precautions Talk to your doctor or pharmacist before taking Ryeqo.</p><p>You should know that most women have reduced or no menstrual bleeding (period) during treatment and for a few weeks afterwards.</p><p>Your doctor will discuss your medical and family history with you. Your doctor will also need to check your blood pressure and make sure you are not pregnant. You may also need a physical examination and additional checks, such as breast examination and a scan to measure how strong your bones are, that will be specific to your medical needs and/or concerns.</p><p>Stop taking Ryeqo and get urgent medical attention if you notice:</p><p>any of the conditions mentioned in the Do not take Ryeqo section.</p><p>if you notice signs of liver disease:</p><p>yellowing of your skin or the whites of your eyes (jaundice).</p><p>nausea or vomiting, fever, severe tiredness.</p><p>dark urine, itching or upper abdominal pain.</p><p>a large rise in your blood pressure (symptoms may be headache, tiredness, dizziness).</p><p>migraine for the first time or unusually bad headaches occurring more often than before.</p><p>if you notice possible signs of a blood clot that may mean you are suffering from a clot in the leg (i.e. deep vein thrombosis), or in the lung (i.e. pulmonary embolism), a heart attack or a stroke. For a description of the symptoms of these serious conditions please go to Ryeqo and risk of blood clots .</p><p>if you become pregnant.</p><p>Tell your doctor if any of the following conditions apply to you:</p><p>if you have one or more of the risk factors for developing a blood clot listed below.</p><p>if you have high blood pressure.</p><p>if you have osteoporosis.</p><p>if you suffer from migraines.</p><p>if you think you might be pregnant. Treatment with Ryeqo usually leads to a significant reduction or may even stop your menstrual bleeding (your period ), making it difficult to recognise pregnancy.</p><p>if you have or previously suffered from depression.</p><p>if you have renal (kidney) disease.</p><p>Ryeqo and risk of blood clots The use of other medicines containing an estrogen and a progestogen increases the risk of blood clots. The risk of blood clots with Ryeqo has not been established. Ryeqo reduces the estrogen to levels similar to those at the beginning of your normal menstrual cycle.</p><p>Factors that can increase your risk of a blood clot in your vein and/or artery:</p><p>as you get older (particularly above about 35 year of age).</p><p>if you are overweight (body mass index > 30 kg/m2).</p><p>if you have had major surgery or prolonged time off your feet (e.g. your leg is in a cast).</p><p>if you have recently given birth.</p><p>if anyone in your close family has had a blood clot in the leg, lung or other organ, a heart attack or a stroke at a young age (e.g. below the age of 50 years).</p><p>if you smoke.</p><p>if you have a problem with your heart (valve disorder, disturbance of the rhythm called atrial fibrillation).</p><p>if you have diabetes.</p><p>if you have certain medical conditions such as systemic lupus erythematosus (SLE - a disease affecting your natural defence system), sickle cell disease (an inherited disease of the red blood cells), Crohn s disease or ulcerative colitis (chronic inflammatory bowel diseases), or cancer.</p><p>The risk of developing a blood clot increases the more factors you have.</p><p>The symptoms of a blood clot will depend on where the blood clot has occurred.</p><p>Symptoms of a blood clot in your leg (deep vein thrombosis; DVT) The symptoms of a blood clot in the leg known as a deep vein thrombosis (DVT) can include:</p><p>swelling in your leg and/or foot or along a vein in your leg.</p><p>pain or tenderness in your leg which feels worse when you stand up or are walking.</p><p>increased heat in the affected leg with red or discoloured skin.</p><p>Symptoms of a blood clot in your lung (pulmonary embolism; PE) The symptoms of a blood clot in the lung known as a pulmonary embolism (PE) can include:</p><p>a sudden onset of unexplained shortness of breath or rapid breathing.</p><p>sudden coughing which may be associated to a sharp pain in your chest.</p><p>coughing up of blood.</p><p>severe dizziness or feeling lightheaded.</p><p>a rapid or irregular heartbeat.</p><p>Symptoms of a heart attack The symptoms of a heart attack, also known as a myocardial infarction, may be temporary and can include:</p><p>pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in your chest, arm, or below your breastbone.</p><p>discomfort radiating to your back, jaw, throat, arm, stomach.</p><p>feeling of being full, having indigestion or choking.</p><p>sweating, nausea, vomiting or dizziness.</p><p>extreme weakness, anxiety, or shortness of breath.</p><p>rapid or irregular heartbeats.</p><p>Symptoms of a stroke The symptoms of a stroke can include:</p><p>a sudden numbness or weakness in your face, arm of leg, especially on one side of your body.</p><p>sudden trouble walking, dizziness, loss of balance or coordination.</p><p>sudden confusion, trouble speaking or understanding others.</p><p>sudden trouble seeing in one or both of your eyes.</p><p>sudden, severe or prolonged headache with no known cause.</p><p>loosing consciousness or fainting with or without a seizure.</p><p>Surgery If you are going to have surgery, tell the surgeon that you are taking Ryeqo.</p><p>Liver tumours or liver disease<br/>In rare cases liver tumours or liver disease has been reported in women taking estrogens and progestogens. If you experience any symptoms of jaundice contact your doctor for further medical advice.</p><p>Renal (kidney) impairment If you experience any decrease in urine production or notice any fluid retention causing swelling in your legs, ankles or feet, please contact your doctor for further medical advice.</p><p>Change in menstrual bleeding pattern (your period ) Treatment with Ryeqo usually leads to a significant reduction or may even stop your menstrual bleeding (your period ) within the first 30 days of treatment. However, if you continue to experience excessive bleeding, tell your doctor.</p><p>Depression If you experience mood changes or any depressive symptoms contact your doctor for further medical advice.</p><p>Increased blood pressure<br/>In rare cases treatment with Ryeqo may lead to small increases in blood pressure. If you experience any symptoms of increased blood pressure, contact your doctor for further medical advice.</p><p>Uterine fibroid prolapse and expulsion Uterine fibroids may develop anywhere within the muscular wall of the uterus, including the submucosa, a thin layer of tissue in the uterus. In some women, the uterine fibroid may protrude or slip through the cervix into the vagina and may lead to significant worsening of uterine bleeding or pain. If you re-experience severe uterine bleeding after your symptoms have improved while being treated with Ryeqo, contact your doctor for medical advice.</p><p>Gallbladder disorders Some women taking estrogen and progestogen hormones including Ryeqo have reported gallbladder disorders (gallstones or inflammation of your gallbladder). If you experience unusually severe pain below your rib cage or in your upper abdomen contact your doctor for medical advice.</p><p>Children and adolescents Ryeqo should not be taken by children under 18 years of age since the safety and efficacy of Ryeqo has not been established in this age group.<br/>Other medicines and Ryeqo Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Talk to your doctor if you are taking any of the medicines listed below, as these medicines can affect Ryeqo or be affected by Ryeqo:</p><p>Certain medicines used to treat epilepsy (e.g. carbamazepine, topiramate, phenytoin, phenobarbital, primidone, oxcarbazepine, felbamate).</p><p>Certain medicines used to treat human immunodeficiency virus infection/ acquired immunodeficiency syndrome (HIV/AIDS) (e.g. ritonavir, efavirenz).</p><p>Certain medicines used to treat Hepatitis C virus (HCV) (e.g. boceprevir, sofosbuvir, velpatasvir, voxilaprevir, telaprevir, glecaprevir).</p><p>Certain medicines used to treat fungal infections (e.g. ketoconazole, itraconazole, fluconazole, griseofulvin).</p><p>Certain medicines used to treat bacterial infections (e.g. rifampicin, rifabutin, clarithromycin, erythromycin, gentamicin, tetracycline, griseofulvin).</p><p>Certain medicine used to treat high blood pressure in the arteries in the lung (e.g. bosentan).</p><p>Certain medicines used to treat high blood pressure (e.g. diltiazem, carvedilol, verapamil).</p><p>Certain medicines used to treat irregular heartbeats (e.g. amiodarone, dronedarone, propafenone, quinidine, verapamil).</p><p>Certain medicines used to treat angina (e.g. ranolazine, carvedilol, verapamil).</p><p>Certain medicines to prevent organ rejection after transplantion (e.g. cyclosporine).</p><p>Herbal remedies containing St John s wort (Hypericum perforatum).</p><p>Pregnancy and breast-feeding Do not take Ryeqo if you are pregnant or breast-feeding. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. If you become pregnant, stop taking Ryeqo and contact your doctor.</p><p>Ryeqo stops ovulation and thus you are not likely to become pregnant while using Ryeqo if used as recommended. Ovulation and menstrual bleeding will return rapidly after discontinuing Ryeqo and alternative birth control needs to be started immediately after discontinuation of Ryeqo.</p><p>Depending on when in your cycle you start taking Ryeqo, it may take time to obtain the full inhibition of ovulation by Ryeqo; therefore, nonhormonal birth control (e.g. condoms) should be used for the first month after starting Ryeqo.</p><p>If you miss two or more tablets in a row, nonhormonal birth control (e.g. condoms) should be used for the next 7 days of treatment.</p><p>Driving and using machines Ryeqo has no known effect on the ability to drive and use machines.</p><p>Laboratory tests If you need a blood or urine test, tell your doctor or the laboratory staff that you are taking Ryeqo because this medicine can affect the results of some tests.</p><p>Ryeqo contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p></div>"
}
},
{
"title" : "3. How to take ryeqo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take ryeqo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br/>The recommended dose is one tablet per day.</p><p>The tablet must be taken orally every day, at about the same time, with or without food with a little liquid.</p><p>It is recommended that you start taking Ryeqo within the first 5 days after the start of bleeding due to your period. If you start at another time of your menstrual cycle, you may initially experience irregular or heavier bleeding.</p><p>If you take more Ryeqo than you should There have been no reports of serious harmful effects from taking several doses of this medicine at once. Large doses of estrogen may cause nausea and vomiting, and vaginal bleeding. If you have taken too many Ryeqo tablets ask your doctor or pharmacist for advice.</p><p>If you forget to take Ryeqo If you miss one tablet, take it as soon as you remember and then resume taking your tablet the next day as usual. Do not take a double dose to make up for a forgotten tablet.</p><p>If you miss two or more tablets in a row, consult with your doctor and use a nonhormonal contraceptive (e.g. condoms) for the next 7 days of treatment.</p><p>If you stop taking Ryeqo<br/>If you would like to stop taking Ryeqo, talk to your doctor first. Your doctor will explain the effects of stopping treatment and discuss other possibilities with you.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Get urgent medical attention if you get any of the following signs and symptoms of an allergic reaction:</p><p>swelling of your lips, face or throat.</p><p>The following side effects have been reported with Ryeqo and are listed below according to the frequency which they occur.</p><p>Very common side effects (may affect more than 1 in 10 people)</p><p>headache,</p><p>hot flush.</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>irritability,</p><p>decreased interest in sex,</p><p>dizziness,</p><p>nausea,</p><p>hair loss,</p><p>increased sweating,</p><p>night sweats,</p><p>joint pain,</p><p>excessive, irregular, or prolonged bleeding from the womb (uterine bleeding),</p><p>dryness of the genital area.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>indigestion,</p><p>hives (urticaria),</p><p>angioedema (rapid swelling of the mucous membranes or the skin that may occur in the face, mouth, tongue, abdomen or arms and legs),</p><p>a lump in the breast tissue (breast cyst),</p><p>uterine myoma expulsion (fibroid comes out either completely or partially through the vagina, usually with increased bleeding from the vagina).</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store ryeqo",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store ryeqo"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on both the outer carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage condition.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Ryeqo contains</p><p>The active substances are relugolix, estradiol and norethisterone acetate. One film-coated tablet contains 40 mg relugolix, 1 mg estradiol and 0.5 mg norethisterone acetate.</p><p>The other ingredients are lactose monohydrate, mannitol (E421), sodium starch glycolate, hydroxypropyl cellulose (E463), magnesium stearate (E572), hypromellose type 2910 (E464), titanium dioxide (E171), triacetin (E1518), iron oxide yellow (E172).</p><p>What Ryeqo looks like and contents of the pack Ryeqo is light yellow to yellow, round, film-coated tablet of 8 mm with 415 on one side, and plain faced on the other side. It is available in high-density polyethylene (HDPE) bottles with desiccant, closed with an induction-sealed child-resistant polypropylene cap or PVC/Al blister with desiccant packed in PET/Al/PE triplex foil sachet. Each box contains one or three bottles with 28 tablets; or two or six blisters with 14 tablets.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder<br/>Gedeon Richter Plc. Gy mr i t 19-21. 1103 Budapest Hungary</p><p>Manufacturer (batch release site) Gedeon Richter Plc. Gy mr i t 19-21. 1103 Budapest Hungary</p><p>This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp2879bea9059649bf46970484a32311c1",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp2879bea9059649bf46970484a32311c1",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp2879bea9059649bf46970484a32311c1\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp2879bea9059649bf46970484a32311c1</b></p><a name=\"mp2879bea9059649bf46970484a32311c1\"> </a><a name=\"hcmp2879bea9059649bf46970484a32311c1\"> </a><a name=\"mp2879bea9059649bf46970484a32311c1-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1565/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Ryeqo 40 mg/1 mg/0.5 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/21/1565/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Ryeqo 40 mg/1 mg/0.5 mg film-coated tablets",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
